What combination regimens containing BCMA-directed bispecific antibodies are being evaluated for MM?

The Multiple Myeloma Hub spoke with Alexander Lesokhin, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What combination regimens containing B-cell maturation antigen (BCMA)-directed bispecific antibodies are being evaluated for multiple myeloma (MM)? In this interview, Lesokhin discussed the range of combination regimens featuring a BCMA-directed bispecific antibody for MM, outlining the rationale for these strategies and noting that while BCMA bispecifics have shown high response rates in the relapsed/refractory setting outcomes can be further improved. Lesokhin reviewed combinations with other bispecific antibodies, established MM therapies, and other novel agents including checkpoint inhibitors and those that can enhance BCMA expression on malignant cells. This educational resource is independently supported by Pfizer. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.